Iron overload is one of the major causes of morbidity in patients with thalassemia major.
Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new …

Deferiprone is an orally active iron chelator which has emerged from an extensive search for
new treatment of iron overload. Comparative studies have shown that at comparable doses …

Data from several trials have provided direct and supportive evidence for the efficacy of
deferiprone in the treatment of iron overload in thalassemia major. Deferiprone has been …

Abstract Background and Objectives The aim of this prospective, randomized, 1-year study
was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations …

The availability of three iron chelators improved the scenario of chelation therapy for
transfusion-dependent thalassemia (TDT) patients, allowing tailoring of drugs according to …

Deferiprone is an orally active iron-chelating agent used in the management of transfusion-
related hemosiderosis. It has been in clinical use for over 20 years and has been shown to …

Introduction: Transfusional iron overload can lead to hepatic fibrosis, arrhythmias and
congestive heart failure and a number of endocrinopathies. Deferiprone is an oral iron …

Introduction: Iron‐chelating therapy with deferoxamine in patients with thalassemia major
has dramatically improved the prognosis of this disease. However, the limitations of this …

Aim Iron chelators are extensively used to reduce iron overload. Our purpose was to
compare effects of deferasirox versus deferasirox and deferoxamine in patients with …

Background To determine whether the orally active iron chelator deferiprone (1, 2-dimethyl-
3-hydroxypyridin-4-one) is efficacious in the treatment of iron overload in patients with …